<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403205</url>
  </required_header>
  <id_info>
    <org_study_id>WTX101-301</org_study_id>
    <nct_id>NCT03403205</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects</brief_title>
  <official_title>A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older With an Extension Phase of up to 60 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilson Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wilson Therapeutics AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Wilson Disease (WD) is an autosomal recessive disorder of impaired copper (CU) transport
      caused by mutations in the ATP7B gene. WTX101 (bis-choline tetrathiomolybdate) is a
      first-in-class copper-protein-binding agent with a unique mechanism of action, under
      investigation as a novel therapy for WD. It is formulated as an enteric coated tablet (15 mg
      strength) for oral administration. The purpose of this study is to evaluate the efficacy of
      WTX101 administered for 48 weeks compared to standard of care (SOC) in WD subjects aged 18
      and older.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, rater-blinded, multi-center study assessing the efficacy and
      safety of an individualized WTX101 dosing regimen administered for 48 weeks, compared to SoC,
      in WD subjects aged 18 and older. Approximately 100 subjects will be enrolled at
      approximately 5 to 10 North American sites and 15 to 25 sites in the rest of the world.
      Subjects who complete the 48-week treatment period will be offered to participate in an
      Extension Phase of the study to evaluate the long-term safety and durability of treatment
      effect of WTX101.

      The primary objective is to evaluate the efficacy of WTX101 administered for 48 weeks,
      compared to SOC, on Cu control in WD subjects aged 18 and older. Copper control will be
      assessed in terms of the percentage change from baseline (Day 1) to 48 weeks in
      non-ceruloplasmin-bound copper (NCC) levels. For WTX101-treated subjects, the NCC level will
      be corrected for the amount of Cu bound to the WTX101 tripartite complex (TPC)
      (NCCcorrected).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">February 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>This study is rater-blinded for the Unified Wilson Disease Rating Scale (UWDRS) assessment only. The rater will be blinded and will have no knowledge of the subject's treatment assignment and no access to systems that could result in potential unblinding of treatment assignment. Both raters and subjects will be instructed to avoid lines of inquiry, questions, and responses that could potentially lead to unblinding of the subject's treatment. The blinding will be documented by the rater after each UWDRS assessment. The rater assessments will be strictly limited to administration of the protocol specified instruments and assessments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of WTX101 using standard of care as comparator and copper as the control assessed in terms of the percentage change from baseline (Day 1) to 48 weeks in non-ceruloplasmin-bound copper levels</measure>
    <time_frame>Change from baseline (Day 1) to 48 weeks</time_frame>
    <description>Evaluate the efficacy of WTX101 administered for 48 weeks, compared to standard of care, on copper control in Wilson Disease subjects aged 18 and older. Copper control will be assessed in terms of the percentage change from baseline (Day 1) to 48 weeks in non-ceruloplasmin-bound copper levels. For WTX101-treated subjects, the non-ceruloplasmin-bound copper level will be corrected for the amount of copper bound to the WTX101 tripartite complex.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of individualized dosing of WTX101 by descriptive statistics via the Safety Analysis Set dataset</measure>
    <time_frame>Change from baseline (Day 1) to 48 weeks</time_frame>
    <description>Safety and tolerability will be determined over the course of the study period by descriptive statistics via the Safety Analysis Set dataset. This dataset includes all subjects who received at least 1 dose of randomized treatment. Subjects will be summarized according to the treatment actually received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of WTX101 on hepatic status</measure>
    <time_frame>Change from baseline (Day 1) to 48 weeks</time_frame>
    <description>Evaluate the effects of WTX101 on hepatic status assessed by the Model for End-Stage Liver Disease (MELD) score. The MELD uses the subject's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. It is calculated according to the following formula:
MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of WTX101 on disability status</measure>
    <time_frame>Change from baseline (Day 1) to 48 weeks</time_frame>
    <description>Evaluate the effects of WTX101 on disability status assessed by the Unified WD Rating Scale (UWDRS) Part II which consists of a historical review of daily activity items and is reported by the subject or family.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of WTX101 on neurological status</measure>
    <time_frame>Change from baseline (Day 1) to 48 weeks</time_frame>
    <description>Evaluate the effects of WTX101 on neurological status assessed by the Unified WD Rating Scale (UWDRS) Part III which consists of a neurological examination performed by a blinded neurologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global effects of WTX101 on clinical symptoms as assessed by the Investigator on the Clinical Global Impression-Improvement Scale (CGI-I) and the Clinical Global Impression-Severity Scale (CGI-S)</measure>
    <time_frame>Change from baseline (Day 1) to 48 weeks</time_frame>
    <description>Evaluate the global effects of WTX101 on clinical symptoms performed by the Investigator using a composite assessment which include the Clinical Global Impression-Improvement Scale (a 7-point scale that assess how much the subject's illness has improved or worsened relative to a baseline and rated from 1 to 7) and the Clinical Global Impression-Severity Scale (a 7-point scale that assess severity of a subject's illness relative to a baseline and rated from 1 to 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of WTX101 on NCC responder rate</measure>
    <time_frame>Change from baseline (Day 1) to 48 weeks</time_frame>
    <description>Evaluate the effects of WTX101 on the NCC responder rate</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Wilson Disease</condition>
  <arm_group>
    <arm_group_label>15-60 mg WTX101 to subjects treated &gt;28 days with SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated for &gt;28 days with chelation or zinc (Zn) therapy or a combination of both chelation and Zn therapy will be treated with 15 mg every other day (QOD) to 60 mg once daily (QD) of WTX101 by oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC for subjects treated with SOC &gt;28 days prior</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects treated for &gt;28 days with chelation or Zn therapy or a combination of both chelation and Zn therapy will continue to receive the SOC therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15-60 mg WTX101 to subjects treated ≤28 days with SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are treatment naïve or have been previously treated with chelation or Zn therapy or a combination of both chelation and Zn therapy for ≤28 days will be treated with 15 mg QOD to 60 mg QD of WTX101 by oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC for subjects treated with SOC ≤28 days prior</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who are treatment naïve or have been previously treated with chelation or Zn therapy or a combination of both chelation and Zn therapy for ≤28 days will initiate or continue SOC therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WTX101</intervention_name>
    <description>WTX101 administered orally in 15 mg tablets</description>
    <arm_group_label>15-60 mg WTX101 to subjects treated &gt;28 days with SOC</arm_group_label>
    <arm_group_label>15-60 mg WTX101 to subjects treated ≤28 days with SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC Therapy</intervention_name>
    <description>Subjects randomized to receive SOC treatment will continue their current therapy or initiate therapy with chelation, Zn, or a combination of both chelation and Zn therapy. Depending on the site/region enrolling the subject, this treatment will be trientine hydrochloride, penicillamine, or Zn, or a combination of both chelation and Zn therapy, administered according to standard regimens.</description>
    <arm_group_label>SOC for subjects treated with SOC &gt;28 days prior</arm_group_label>
    <arm_group_label>SOC for subjects treated with SOC ≤28 days prior</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who meet all of the following criteria will be eligible to participate in the
        study:

          -  Established diagnosis of WD by Leipzig-Score ≥4 documented by testing as outlined in
             the 2012 European Association for the Study of Liver WD Clinical Practice Guidelines;

          -  Treatment for &gt;28 days for WD with chelation therapy (ie, penicillamine, trientine
             hydrochloride), Zn therapy, or a combination of a chelator and Zn; OR Treatment naïve
             or treatment for ≤28 days for WD with chelation therapy (ie, penicillamine, trientine
             hydrochloride), Zn therapy, or a combination of a chelator and Zn;

          -  Willing and able to give informed consent for participation in the study;

          -  Male or female subjects, aged 18 years or older as of signing the informed consent
             form (ICF);

          -  Able to understand and willing to comply with study procedures, restrictions, and
             requirements, as judged by the Investigator;

          -  Willing to undergo ≥48-hour washout from current WD treatment;

          -  Adequate venous access to allow collection of required blood samples;

          -  Willing to avoid use of vitamins and/or minerals containing Cu, Zn, or Mo throughout
             the study duration;

          -  Willing to avoid intake of foods and drinks with high contents of Cu throughout the
             study duration;

          -  Females of childbearing potential will be included if they are either sexually
             inactive (abstinent) for 14 days prior to the first WTX101 dose and continuing through
             28 days after the last WTX101 dose, or using 1 of the following highly effective birth
             control methods (ie, results in &lt;1% failure rate when used consistently and
             correctly):

               1. Intrauterine device (without Cu) in place for at least 3 months prior to the
                  first WTX101 dose and throughout the study;

               2. Surgical sterilization of the partner (vasectomy for 6 months minimum);

               3. Combined (estrogen or progestogen containing) hormonal contraception associated
                  with the inhibition of ovulation (either oral, intravaginal, or transdermal) for
                  at least 3 months prior to the first WTX101 dose and throughout the study;

               4. Progestogen only hormonal contraception associated with the inhibition of
                  ovulation (either oral, injectable, or implantable) for at least 3 months prior
                  to the first WTX101 dose and throughout the study;

               5. Intrauterine hormone releasing system for at least 3 months prior to the first
                  WTX101 dose and throughout the study; or

               6. Bilateral tubal occlusion for at least 6 months prior to the first WTX101 dose;

                    -  Note: Sexual abstinence is considered a highly effective method only if
                       defined as refraining from heterosexual intercourse during the entire period
                       of risk associated with the study treatments. In this trial, abstinence is
                       only acceptable if in line with the subject's preferred and usual lifestyle;
                       and

                    -  Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods),
                       withdrawal (coitus interruptus), spermicides only, and lactational
                       amenorrhoea method are not acceptable methods of contraception. As well,
                       female condom and male condom should not be used together;

          -  Females of childbearing potential agree to remain sexually inactive or to keep the
             same birth control method for at least 28 days following the last dose;

          -  A female of non-childbearing potential must have undergone 1 of the following
             sterilization procedures at least 6 months prior to the first WTX101 dose:

               1. Hysteroscopic sterilization;

               2. Bilateral tubal ligation or bilateral salpingectomy;

               3. Hysterectomy; or

               4. Bilateral oophorectomy; OR be postmenopausal with amenorrhoea for at least 1 year
                  prior to the first WTX101 dose and follicle stimulating hormone serum levels
                  consistent with postmenopausal status;

          -  A non-vasectomized male subject agrees to use a condom with spermicide or abstain from
             sexual intercourse during the study until 90 days beyond the last dose of study drug.
             For a vasectomized male who has had his vasectomy 6 months or more prior to study
             start, it is required that they use a condom during sexual intercourse. A male who has
             been vasectomized less than 6 months prior to study start must follow the same
             restrictions as a non-vasectomized male;

               -  Note: Sexual abstinence is considered a highly effective method only if defined
                  as refraining from heterosexual intercourse during the entire period of risk
                  associated with the study treatments. In this trial, abstinence is only
                  acceptable if in line with the subject's preferred and usual lifestyle; and

               -  Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods),
                  withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea
                  method are not acceptable methods of contraception. As well, female condom and
                  male condom should not be used together; and

          -  If male, agrees not to donate sperm from the first WTX101 dose until 90 days after
             dosing.

        Exclusion Criteria:

        Subjects who meet any of the following criteria will be excluded from participation in the
        study:

          -  Decompensated hepatic cirrhosis;

          -  MELD score &gt;13;

          -  Modified Nazer score &gt;7;

          -  Clinically significant gastrointestinal bleed within past 3 months;

          -  Alanine aminotransferase &gt;2 × upper limit of normal (ULN) for subjects treated for &gt;28
             days with WD therapy (Cohort 1);

          -  Alanine aminotransferase &gt;5 × ULN for treatment naïve subjects or subjects who have
             been treated for ≤28 days (Cohort 2);

          -  Marked neurological disease requiring either nasogastric feeding or intensive
             inpatient medical care;

          -  Severe anaemia with a hemoglobin &lt;9 g/dL;

          -  Participation in a clinical study of an experimental or unapproved/unlicensed therapy
             at the same time or within the 4 weeks prior to this Screening Visit;

          -  History of seizure activity within 6 months of study start;

          -  Pregnant (or women who are planning to become pregnant) or lactating women;

          -  Known sensitivity to WTX101, WTX101 excipients (anhydrous di-calcium phosphate,
             anhydrous sodium carbonate), or any of the ingredients contained in WTX101 or related
             compounds;

          -  Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C
             virus (subjects with positive hepatitis C antibody result would require confirmation
             of active disease with a positive hepatitis C polymerase chain reaction test), or
             seropositivity for human immunodeficiency virus;

          -  Any disability acquired from trauma or another illness that, in the opinion of the
             Investigator, could interfere with evaluation of disability due to WD;

          -  Previous treatment with tetrathiomolybdate;

          -  Major systemic disease or other illness that would, in the opinion of the
             Investigator, compromise subject safety or interfere with the collection or
             interpretation of study results;

          -  In the opinion of the Investigator, the subject is likely to be non-compliant or
             uncooperative during the study; or

          -  Any deviation in laboratory values that are confirmed on re-examination to be
             clinically significant by the Investigator that would jeopardize the safety of the
             subject or impact the validity of the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Bjartmar, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Wilson Therapeutics AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA) - David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Yang</last_name>
      <email>ddyang@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Jeff Bronstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Swift</last_name>
      <email>sarah.swift@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Schilsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University The Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ZsaZsa Brown</last_name>
      <email>zsazsa.brown@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Danny Bega</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Wu</last_name>
      <phone>734-764-4048</phone>
      <email>elizwu@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Fred Askari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240-7915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tricia McKinney</last_name>
      <phone>615-875-7394</phone>
      <email>tricia.r.mckinney@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Hedera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Hunsucker</last_name>
      <phone>832-355-1450</phone>
      <email>tzgabay@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Norman Sussman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Whiting</last_name>
      <phone>206-987-5634</phone>
      <email>christopher.whiting@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Sihoun Hahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Klemens Zotter</last_name>
      <phone>+43 512 504 82830</phone>
      <email>klemens.zotter@tirol-kliniken.at</email>
    </contact>
    <investigator>
      <last_name>Heinz Zoller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien, Innere Medizin III</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Swoboda</last_name>
      <phone>+43 (0)1 40400-47440</phone>
      <email>Anna.swoboda@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Peter Ferenci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Radan Bruha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon- Hopital Femme- Mere-Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdelouahed BelMalih</last_name>
      <email>Abdelouahed.BELMALIH@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Sophie Brunet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadege Tinant</last_name>
      <email>nadege.tinant@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Aurelia Poujois</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ulrike Reuner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ifi - Studien und Projekte GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petra Lange</last_name>
      <phone>+49402840760201</phone>
      <email>lange@ifi-medizin.de</email>
    </contact>
    <investigator>
      <last_name>Peter Buggisch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Langel</last_name>
      <phone>49-(0)6221- 56 8388</phone>
      <email>Andrea.Langel@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Karl-Heinz Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum der Universitaet Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carolin Straube</last_name>
      <phone>+493419712328</phone>
      <email>carolin.straube@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Wiegand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ferenc Szalay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Orly Azulay</last_name>
      <phone>972522976633</phone>
      <email>orlyaz@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Eli Zuckerman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rami Ghantous</last_name>
      <email>ghantous@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Rifaat Safadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Avishag Hassid</last_name>
      <phone>972-35307176</phone>
      <email>avishag.hassid@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ziv Ben Ari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo - Milano</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Orellana</last_name>
      <email>daniel.orellana.r@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Massimo Zuin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giusy Ranucci</last_name>
      <email>giusyranucci@hotmail.it</email>
    </contact>
    <investigator>
      <last_name>Raffaele Iorio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Rigo</last_name>
      <email>alessandra.rigo@hotmail.it</email>
    </contact>
    <investigator>
      <last_name>Renata D'Incà</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio - Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Ainscough</last_name>
      <email>ricercaparkinson@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Pellecchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Psychiatrii i Neurologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomasz Litwin</last_name>
      <email>tomlit@medprakt.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Czlonkowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli - Hospital de Sabadell</name>
      <address>
        <city>Barcelona</city>
        <zip>E-08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ariadna Figuerola</last_name>
      <phone>0034937231010 ext 22070</phone>
      <email>AFiguerola@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Mercedes Vergara Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Gomez</last_name>
      <email>mgadelhuph@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose Luis Calleja Panero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vanessa Hontagas</last_name>
      <phone>+34 96 124 58 56</phone>
      <email>vahonpla@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marina Berenguer Haym</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2PR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire Arthur</last_name>
      <email>claire.arthur@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Nicholl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0OQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>William Griffiths</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vicky Westall</last_name>
      <email>victoria.westall@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Aftab Ala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

